Adjunctive therapy of severe sepsis and septic shock in adults

Dellinger, 2008, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008, Intensive Care Med, 34, 17, 10.1007/s00134-007-0934-2 Vincent, 2006, Sepsis in European intensive care units: results of the SOAP study, Crit Care Med, 34, 344, 10.1097/01.CCM.0000194725.48928.3A Marik, 2008, Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine, Crit Care Med, 36, 1937, 10.1097/CCM.0b013e31817603ba Annane, 2006, Diagnosis of adrenal insufficiency in severe sepsis and septic shock, Am J Respir Crit Care Med, 174, 1319, 10.1164/rccm.200509-1369OC Annane, 2004, Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis, BMJ, 329, 480, 10.1136/bmj.38181.482222.55 Bollaert, 1998, Reversal of late septic shock with supraphysiologic doses of hydrocortisone, Crit Care Med, 26, 645, 10.1097/00003246-199804000-00010 Briegel, 1999, Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study, Crit Care Med, 27, 723, 10.1097/00003246-199904000-00025 Annane, 2002, Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock, JAMA, 288, 862, 10.1001/jama.288.7.862 Sprung, 2008, Hydrocortisone therapy for patients with septic shock, N Engl J Med, 358, 111, 10.1056/NEJMoa071366 Absalom, 1999, Adrenocortical function in critically ill patients 24 h after a single dose of etomidate, Anaesthesia, 54, 861, 10.1046/j.1365-2044.1999.01003.x Bernard, 2001, Efficacy and safety of recombinant human activated protein C for severe sepsis, N Engl J Med, 344, 699, 10.1056/NEJM200103083441001 Angus, 2004, The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis, Crit Care Med, 32, 2199, 10.1097/01.CCM.0000145228.62451.F6 Vincent, 2003, Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial, Crit Care Med, 31, 834, 10.1097/01.CCM.0000051515.56179.E1 Pocock, 2005, When (not) to stop a clinical trial for benefit, JAMA, 294, 2228, 10.1001/jama.294.17.2228 Kubler, 2006, Results of severe sepsis treatment program using recombinant human activated protein C in Poland, Med Sci Monit, 12, CR107 Vincent, 2005, Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment, Crit Care Med, 33, 2266, 10.1097/01.CCM.0000181729.46010.83 Abraham, 2005, Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death, N Engl J Med, 353, 1332, 10.1056/NEJMoa050935 Laterre, 2007, ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation, Crit Care Med, 35, 1457, 10.1097/01.CCM.0000266588.95733.63 Rowan, 2008, Drotrecogin alfa (activated): real-life use and outcomes for the UK, Crit Care, 12, R58, 10.1186/cc6879 Muller, 2008, Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study, Intensive Care Med, 34, 977, 10.1007/s00134-008-0997-8 Laterre, 2007, International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety, J Crit Care, 22, 142, 10.1016/j.jcrc.2006.09.007 Vincent, 2008, A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units – an observational study, Acta Clin Belg, 63, 25, 10.1179/acb.2008.004 Bertolini, 2007, Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey, Intensive Care Med, 33, 426, 10.1007/s00134-007-0554-x Barie, 2006, Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis, Surg Infect (Larchmt), 7, S77, 10.1089/sur.2006.7.s2-77 Van Den, 2001, Intensive insulin therapy in the critically ill patients, N Engl J Med, 345, 1359, 10.1056/NEJMoa011300 Van Den, 2006, Intensive insulin therapy in the medical ICU, N Engl J Med, 354, 449, 10.1056/NEJMoa052521 Finfer, 2009, Intensive versus conventional glucose control in critically ill patients, N Engl J Med, 360, 1283, 10.1056/NEJMoa0810625 Vriesendorp, 2006, Evaluation of short-term consequences of hypoglycemia in an intensive care unit, Crit Care Med, 34, 2714, 10.1097/01.CCM.0000241155.36689.91 Brunkhorst, 2008, Intensive insulin therapy and pentastarch resuscitation in severe sepsis, N Engl J Med, 358, 125, 10.1056/NEJMoa070716 Van Cromphaut, 2008, Glucose metabolism and insulin resistance in sepsis, Curr Pharm Des, 14, 1887, 10.2174/138161208784980563 Ronco, 2007, The immunomodulatory effect of extracorporeal therapies in sepsis: a reconciliation of three theories, Int J Artif Organs, 30, 855, 10.1177/039139880703001001 Ronco, 2002, Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial, EDTNA ERCA J, 2, 7, 10.1111/j.1755-6686.2002.tb00248.x Ratanarat, 2005, Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival, Crit Care, 9, R294, 10.1186/cc3529 Formica, 2003, Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock, Intensive Care Med, 29, 703, 10.1007/s00134-003-1724-0 Cruz, 2007, Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review, Crit Care, 11, R47, 10.1186/cc5780 Shimizu, 2006, Endotoxin apheresis for sepsis, Transfus Apher Sci, 35, 271, 10.1016/j.transci.2006.06.006 Kulabukhov, 2008, Use of an endotoxin adsorber in the treatment of severe abdominal sepsis, Acta Anaesthesiol Scand, 52, 1024, 10.1111/j.1399-6576.2008.01677.x Ala-Kokko, 2009, Lipopolysaccharide adsorber in abdominal septic shock, Crit Care, 13, 280, 10.1186/cc7444 Blomquist S, Gustafsson V, Manolopolos T, Pierre L. Clinical experience with a novel endotoxin adsorption device in patients undergoing cardiac surgery. J Perfusion; in press. Yaroustovsky, 2009, Experience with the use of selective sorbents in complex intensive care of sepsis in patients after cardiac surgery, Crit Care, 13, 281, 10.1186/cc7445